Servier key figures
key figures
We help to drive therapeutic progress
As a global pharmaceutical Group, we help to drive therapeutic progress by investing over 20% of revenue from brand-name medicines in R&D each year.
About Servier
34th
largest pharmaceutical group worldwide
2nd
largest French pharmaceutical group
20%
Over 20% of revenue from brand-name medicines invested in R&D each year
70
Over 70 scientific partnerships and collaborations in 2021/2022
21,400
employees
97%
of the active ingredients used in the Group’s brand-name medicines are produced by Servier in France
29
international patient organizations collaborated with Servier in 2021/2022
Driving scientific and medical progress
4
therapeutic areas: oncology, cardiometabolism, neuroscience and immuno-inflammation
43
projects in clinical development (including 17 new molecular entities) and 32 research projects (January 2023)
3rd
leading pharmaceutical group in cardiology worldwide
2nd
leading pharmaceutical group in hypertension worldwide
Global presence
150
Over 150 countries where the Group’s medicines are distributed
16
production sites
6
research centers
3
hubs (North and South America, Europe, Asia-Pacific) with 15 International Centers for Therapeutic Research
Social responsibility
25%
reduction in our greenhouse gas emissions between 2016 and 2030
40%
Target to appoint women to at least 40% of senior management positions within the Servier Group by 2024
4.23/5
Overall engagement score achieved by the Servier Group2
Financial performance
€4.9
billion in revenue in 2021/2022
(including €3.7 billion for brand-name medicines and €1.2 billion for generic activities)
€859
million in EBITDA in 2021/2022
[1] IQVIA, Analytics Link / World 74 countries – MAT Q4-2022
[2] Source: annual engagement survey conducted with the Gallup Institute – 2022 Group results